ストックスクリーナーアプリを入手
27.09
3.15%
-0.81
前日終値:
$27.90
開ける：
$27.9
24時間の取引高:
713.45K
Relative Volume:
0.19
時価総額：
$17.91B
収益：
$956.00K
当期純損益:
$-221.32M
株価収益率:
-84.66
EPS:
-0.32
ネットキャッシュフロー:
$-142.25M
1週間 パフォーマンス:
+12.07%
1か月 パフォーマンス:
+55.65%
6か月 パフォーマンス:
+32.52%
1年 パフォーマンス:
+515.49%
1日の値動き範囲:
$26.71
$28.19
1週間の範囲:
$22.84
$29.99
52週間の値動き範囲:
$2.10
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
27.04 | 17.91B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.84 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.51 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
653.20 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.18 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.52 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN
Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey
These 10 Firms Soared Last Week, Here’s Why - Insider Monkey
Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey
This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail
Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus
Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus
Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus
Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus
Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus
Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa
Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com
Summit Therapeutics stock holds $44 target despite drop - Investing.com
Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India
Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada
Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com
Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market Overreaction | SMMT Stock News - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN
Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus
Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı
BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı
Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus
Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus
Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize
Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks
Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus
Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade
Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus
Summit Therapeutics (SMMT) Sees Stock Drop Despite Positive Drug - GuruFocus
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
0.75%
0.70%
大文字化:
|
ボリューム (24 時間):